A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Автор: | Karim, Azrin |
---|---|
Інші автори: | Islam, Farzana |
Формат: | Project report |
Мова: | English |
Опубліковано: |
Brac University
2024
|
Предмети: | |
Онлайн доступ: | http://hdl.handle.net/10361/24372 |
Схожі ресурси
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
за авторством: Islam, Saidul
Опубліковано: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
за авторством: Ahmed, Nafisa
Опубліковано: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
за авторством: Meem, Manila
Опубліковано: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
за авторством: Hossain, Sadman Sanjid
Опубліковано: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
за авторством: Jahan, Nusrat
Опубліковано: (2024)